Julphar 2025 results: Revenue up 8.4% to AED 1.075bn as net profit rises to AED 173.3m
Julphar 2025 results show AED 1,075.5 million revenue and AED 173.3 million net profit, with stronger EBITDA and expanded product registrations.
Julphar reported a strong set of full-year results for the period ended December 31, 2025, delivering growth across top-line and profitability metrics. The Julphar 2025 results include revenue of AED 1,075.5 million, an 8.4% increase from the prior year, and a net profit of AED 173.3 million. Management attributed the performance to operational resilience, improved margins and a focused product-registration drive across domestic and international markets.
Financial performance for year ended December 31, 2025
Julphar posted revenues from continuing operations of AED 1,075.5 million for the financial year, rising 8.4% year-on-year. The company reported an operating profit from continuing operations of AED 43.9 million, reflecting improved core business performance.
EBITDA increased by 22.2% to AED 109.4 million, a sign of tighter cost control and higher operating leverage. Net profit for the year reached AED 173.3 million, underpinned by both operational gains and non-operating items disclosed by the company.
Profitability drivers and margin trends
The jump in EBITDA and net profit signals a meaningful improvement in Julphar’s margin profile during 2025. Management pointed to enhanced administrative and financial efficiency as key contributors to the gains. The combination of revenue growth and disciplined expense management supported a healthier earnings mix compared with the prior year.
The operating profit figure from continuing operations indicates that core manufacturing and sales activities have begun to generate more reliable cash flow. Analysts and investors will likely watch whether the company can sustain margin expansion as it scales new product launches and international registrations.
Product registrations and geographic expansion
Julphar continued to expand its product footprint in 2025, recording 14 new product registrations in the UAE and 25 international registrations across its target markets. The company said these registrations formed part of its “Growth 2030” plan to broaden therapeutic reach and penetrate higher-growth markets.
Management highlighted that the registrations reflect both generics and specialty products, strengthening the firm’s portfolio diversity. The registration push is intended to convert regulatory approvals into market launches and revenue streams over the coming quarters.
Management comments and strategic direction
Sheikh Saqr bin Humaid Al Qasimi, Chairman of Julphar’s board, described the results as validation of the company’s strategic direction and long-term value plan. He said the firm preserved a solid financial position that supports future ambitions and cited shareholder confidence and staff efforts as central to the year’s successes.
Chief Executive Bassel Ziada noted Julphar’s adaptability to market dynamics, stressing the company’s emphasis on innovation and geographic expansion. He said the firm prioritized registrations and market access during 2025, aligning operational activity with the Growth 2030 strategy.
Corporate governance and board election
Shareholders convened at Julphar’s annual general meeting where a new board of directors was elected for the current cycle. The company reported that investors expressed confidence in the newly elected board’s ability to continue creating sustainable long-term value. The board election completes a governance cycle that management says will steer strategic execution and oversight through the next phase of growth.
The vote outcome will now guide corporate priorities and provide governance continuity as the company implements its medium-term plans. Market participants will monitor board composition for signals on capital allocation, international expansion and potential partnership strategies.
Implications for the UAE pharmaceutical sector
Julphar’s 2025 performance underscores the resilience of UAE-based pharmaceutical manufacturers amid regional and global headwinds. The combination of local registrations and outward-looking commercial efforts shows how Emirati firms are leveraging domestic capacity while targeting export markets. The firm’s results may spur increased investor interest in regional healthcare manufacturing and innovation initiatives.
Rising EBITDA and net profit provide Julphar with greater financial flexibility to invest in research and development, regulatory filings and distribution channels. Observers will be watching how Julphar translates approvals into sales and whether investment in new product categories will accelerate revenue diversification.
Julphar’s 2025 results mark a milestone in a multi-year recovery and growth plan, with management projecting continued focus on product approvals, margin improvement and geographic diversification. The company’s strengthened financial profile positions it to pursue strategic priorities while navigating competitive pressures and regulatory environments.